The main goal of the Drug Translation and Development Core Is to facilitate each scientific project in the development of potential radiation mitigators for various organ systems, including lung (Project 1), CNS (Project 2), skin (Project 3), and bone marrow (Project 4) in the context of a total body radiation exposure. This Core will monitor the progress of testing these agents with respect to the efficacy, safety, toxicology, pharmacokinetics, pharmacodynamics, and quality assurance. As a result, Core D hopes to be able to make recommendations regarding regulatory requirement and, ultimately, will be in a position to recommend strategies towards the development of clinical studies and ultimate drug approval by FDA.

Public Health Relevance

Each Project has candidate agents for radiation mitigation, with several agents being tested across Projects. The drug development process will be focused on pre-clinical development. The formulation of the agents and pre-clinical development in animal models will be centrally recorded and efficacy validated by central statistical analyses (see Biostatistics). The stepwise approach of pre-clinical pharmacology will include demonstration of efficacy in vivo in organs of interest (see all project Research Plans), as well as pharmacokinetics and pharmacodynamic investigations in animal injury models, including combined injury. Candidate agents with promising efficacy and low toxicity in animal models may be considered for clinical development through independent funding.

Agency
National Institute of Health (NIH)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI091036-05
Application #
8705382
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
City
Rochester
State
NY
Country
United States
Zip Code
14627
Evans, Andrew G; Calvi, Laura M (2015) Notch signaling in the malignant bone marrow microenvironment: implications for a niche-based model of oncogenesis. Ann N Y Acad Sci 1335:63-77
Frisch, Benjamin J; Calvi, Laura M (2014) Hematopoietic stem cell cultures and assays. Methods Mol Biol 1130:315-24
Niswander, Lisa M; Fegan, Katherine H; Kingsley, Paul D et al. (2014) SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury. Blood 124:277-86
Gopal, Radha; Rangel-Moreno, Javier; Fallert Junecko, Beth A et al. (2014) Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection. Am J Pathol 184:55-63
Gao, Feng; Fish, Brian L; Szabo, Aniko et al. (2014) Enhanced survival from radiation pneumonitis by combined irradiation to the skin. Int J Radiat Biol 90:753-61
O'Banion, M Kerry (2014) Does peripheral inflammation contribute to Alzheimer disease? Evidence from animal models. Neurology 83:480-1
Hoffman, Corey M; Calvi, Laura M (2014) Minireview: complexity of hematopoietic stem cell regulation in the bone marrow microenvironment. Mol Endocrinol 28:1592-601
Cherry, Jonathan D; Olschowka, John A; O'Banion, M Kerry (2014) Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 11:98
Gopal, Radha; Monin, Leticia; Slight, Samantha et al. (2014) Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 10:e1004099
Gopal, Radha; Monin, Leticia; Torres, Diana et al. (2013) S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir Crit Care Med 188:1137-46

Showing the most recent 10 out of 21 publications